OR WAIT null SECS
July 20, 2022
Article
An analysis of data from more than 8400 postmenopausal women with a history of early-stage nonmetastatic, ER-positive breast cancer suggests there was no increase in risk of breast cancer recurrence or mortality observed with use of vaginal estrogen therapy or menopausal hormone therapy.
July 07, 2022
A study of more than 15,000 patients from a national insurance research database suggests older patients with hypothyroidism had an 81% increase in risk of having dementia compared to their counterparts without hypothyroidism.
June 20, 2022
Data from Sweden national registers provide insight into the increased risk of adverse outcomes, including fracture, cardiovascular events, and mortality risk, associated with primary hyperparathyroidism as well as the apparent reductions in risk achieved by undergoing parathyroidectomy.
June 01, 2022
Dr. Gregory Weiss examines a recent study that detailed the risk of cardiovascular disease associated with under- and over-treatment with thyroid hormone therapy.
May 28, 2022
Our endocrine month in review spotlights the most popular articles from the past month. This month's top articles include the approval of tirzepatide, news from AACE & ATTD, and a pair of podcast episodes.
May 13, 2022
A systematic review and meta-analysis from AACE 2022 provides an overview of the potential associations between thyroid dysfunction, including both hypothyroidism and hyperthyroidism, and risk of Parkinson disease.
May 12, 2022
Data presented at AACE 2022 detail levoketoconazole-specific effects observed among patients with endogenous Cushing's syndrome from the phase 3 LOGICS trial.
April 27, 2022
A retrospective cohort study provides evidence suggesting higher TSH levels were linked to increased lengths of stay and greater readmission risks among patients with hypothyroidism.
March 29, 2022
On March 29, Antares Pharma announced the FDA granted approval to their oral testosterone replacement therapy option, testosterone udecanoate (TLANDO), for conditions associated with a deficiency or absence of endogenous testosterone or hypogonadism in adult males.
March 23, 2022
An analysis of nationwide data from Sweden provides an overview of the increased risk of death associated with Cushing's disease was present even after biochemical remission.